Dr. Javier Garde Noguera

Datos del profesional

Áreas de especialización

• Tumores Torácicos.
• Tumores Genitourinarios.
• Tumores de Cabeza y Cuello.

Formación

• Licenciado en Medicina en 2001 por la Universidad Miguel Hernández de Elche.
• Diploma de estudios avanzados por la Facultad de Medicina de la Universidad Autónoma de Barcelona (2006).
• Máster en Oncología Molecular por el Centro Nacional de Investigaciones Oncológicas (CNIO) en 2009.
• Doctor en Medicina por la Universidad de Valencia (2017).
• Desde 2016 Profesor Asociado en la Facultad de Medicina de la Universidad CEU San Pablo de Valencia

Experiencia

- Especialista en Oncología Médica vía MIR en el Hospital General Universitario de Valencia entre 2002 y 2006.
- Posteriormente he trabajado como adjunto en los Servicios de Oncología Médica de
- Hospital Universitario de San Juan de Alicante (2006-2008).
- Hospital Arnau de Vilanova de Valencia (2008-2010).
- Hospital Marinasalud de Denia (2010-2011).
- Hospital Arnau de Vilanova de Valencia (2011 hasta la actualidad).
- Hospital Vithas Castellón desde 2011 hasta la actualidad.

Experiencia académica

Profesor Asociado de la Facultad de Medicina de la Universidad CEU San Pablo de Valencia desde 2016.

Publicaciones

Publicaciones
Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients efficacy and tolerability; Camps C, Caballero C, Blasco A, Safont MJ, Berrocal A, Garde J, Juarez A, Sirera R, Bremnes RM. Anticancer Res. 2005 Nov-Dec;25(6C)4611-4

Quantification in the serum of the catalytic fraction of reverse telomerase a useful prognostic factor in advanced non-small cell lung cancer. Camps C, Sirera R, Bremnes RM, Ródenas V, Blasco A, Safont MJ, Garde J, Juarez A, Caballero C, Sanchez JJ, Taron M, Rosell R. Anticancer Res. 2006 Nov-Dec;26(6C)4905-9

Analysis of c-kit expression in small cell lung cancer prevalence and prognostic implications. Camps C, Sirera R, Bremnes RM, Garde J, Safont MJ, Blasco A, Berrocal A, Sánchez JJ, Calabuig C, Martorell M. Lung Cancer. 2006 Jun;52(3)343-7. Epub 2006 Mar 30

Anaemia as a prognostic factor in small cell lung cancer. Javier Garde, Carlos Camps, Ana Blasco, María José Safont, Rafael Sirera, Cristina Caballero, Asunción Juárez. Supportive & Palliative Cancer Care, 01 June 2007, vol./is. 3/2(71-76).

Optimisation of the use of antithrombotic agents. Camps C, Juárez A, Iranzo V, Garde J, Blasco A, Sirera R Venous thromboembolic disease in cancer. Clin Transl Oncol. 2007 Mar;9(3)161-71

Adverse cutaneous reactions to erlotinib. Pitarch G, Garde J, Torrijos A, Juárez A, Febrer MI, Camps C. Actas Dermosifiliogr. 2008 Jan-Feb;99(1)54-60.
Analysis of the elderly patient population in a tertiary-care university hospital. Juárez A, Garde J, Caballero C, Iranzo V, Gavilá J, Safont M, Blasco A, Camps C. Eur J Cancer Care (Engl). 2009 Jan 23

Primary squamous cell carcinoma of the ovary associated with endometriosis. Acien P, Abad M, Mayol MJ, Garde J. Int J Gynaecol Obstet 2010;10816-20
Phase II trial of concomitant neoaddjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer. J Gastrointest Canc DOI 10.1007/s2029-012-9364-7

Role of Primay tumour resection and addition of bevacizumab to chemotherapy in the management of advanced colorectal cancer with inoperable metastasis a retrospective analysis. Garde Noguera J, Evgenyeva E, Gil Raga M, et al . Journal of Analytical Oncology, 2013;2209-217

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer the BRCA1-RAP80 Expression Customization Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.. Ann Oncol. 2014 Nov;25(11)2147-55. doi 10.1093/annonc/mdu389. Epub 2014 Aug 27.

Carboplatin, Paclitaxel and Bevacizumab versus Cisplatin and Pemetrexed for Non-Small-Cell Lung Cancer. Sangrador Pelluz C, Garde Noguera J, Perez-Serrano Lainosa MD, et al .European Journal of Clinical Pharmacy, 2014;16.

Cisplatin, docetaxel and 5 Fluorouracil followed by pegfilgastrim support and cisplatin in head and neck cancer. Gasent Blesa JM. Poquet Jornet J, Garde Noguera J, et al. Eur J Clin Pharm, 2014;16399-408.

Quantification of circulating endothelial cells as a predictor of response to chemotherapy with platinum and pemetrexed in patients with advanced non-squamous non-small cell lung carcinoma. Aparisi Aaprisi F, Blanco Guerrero R, Calot Tort S, Esquerdo Galiana G, García Piñón F, Garde Noguera J ,Juan VIdal O, Losa Gaspá F, Macia Esclante S, Sanchez Hernandez A, Vidal Martinez J. Clinical and Translational Oncology,2015;174.

Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial. Juan Ó1, Aparisi F2, Sánchez-Hernández A3, Muñoz-Langa J4, Esquerdo G5, García-Sánchez J6, López A7, Garde J6, Giner V8Clin Lung Cancer. 2015 May;16(3)193-9. doi 10.1016/j.cllc.2014.11.006. Epub 2014 Nov 23.

Advanced colorectal cancer Clinico-Pathological and molecular factors with prognostic importance, and potential predictive markers of response to modern systemic treatments. Garde-Noguera J and Gil-Raga M. Journal of Analytical Oncology, 2016,Vol5,Nº1

Peritoneal Carcinomatosis and multi-organ metastases are prognostic factors in colorectal cancer a retrospective analysis. Garde-Noguera J, Gil Raga M, Juarez-Marroqui A, et al. Journal of Analytical Oncoloy,2016;55-13

High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab. Garde-Noguera J, Gil-Raga M, Evgenyeva E, et al. Clin Transl Oncol 2015;0151378-8

Role of Primay tumour resection and addition of bevacizumab to chemotherapy in the management of advanced colorectal cancer with inoperable metastasis a retrospective analysis. Garde Noguera J, Evgenyeva E, Gil Raga M, et al. Journal of Analytical Oncology, 2013,2,209-217

Garde-Noguera J, Gil-Raga M, Evgenyeva E, Bernet L, Llombart-Cussac A and Camps-Herrero C. Lactate Dehydrogenase-5 (Ldh-5) Immunohistochemical Expression as Predictor of Efficacy of First-Line Therapy in Patients with Advanced Colorectal Cancer Treated with Chemotherapy and Bevacizumab. J CLin Exp Pathol, 2016;6293

Garde-Noguera J, Jantus-Lewitntre E, Gil-Raga M, Evgenyeva E, Macia-Esalante S, Llombart-Cussac A and Camps-Herrero C. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab A retrospective analysis. Mol Clin Oncol, 2017;6403-408.

Pertenece a

• Grupo Español de Cáncer de Pulmón.
• Sociedad Española de Oncología Médica.

Proyectos I+D

- Análisis de expresión inmuno-histoquímica de ERCC1, Timidilato Sintetasa, LDH5 y KDRp como marcadores pronósticos y predictivos de respuesta en pacientes con carcinoma colorectal (CCR) avanzado tratados con FOLFOX/XELOX-Bevacizumab.
INVESTIGADOR PRINCIPAL Javier Garde Noguera

- Re-estadiaje con PET-TAC y fibrobroncoscopia ecoguiada (EBUS) en pacientes con carcinoma no microcítico de pulmón (CNMP) EIII irresecable tratados con quimio-radioterapia concomitante.
INVESTIGADOR PRINCIPAL Javier Garde Noguera